LONDON – The UK's major medical research bodies have come out in favor of the use of gene editing in preclinical research, including the use of the technology in human reproductive cells and early embryos. Read More
A risk-defraying pact between Amgen Inc. and Novartis AG will align the companies' early stage efforts to fight Alzheimer's disease (AD) behind Novartis' phase I/II oral beta-site APP-cleaving enzyme-1 (BACE) inhibitor, CNP-520, while also enlisting Novartis as a co-developer and eventual co-seller of Amgen's two migraine candidates in markets beyond North America and Japan. Read More
Researchers at Queens University Belfast have developed a nanoparticle that could dampen inflammatory responses and improve survival in animal models of both sepsis and acute respiratory distress syndrome, both major causes of death and disability in hospitalized patients. Read More
Incyte Corp. leveraged its positive cash flow to invest in its immuno-oncology (I-O) future through a license and collaboration agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop and commercialize anti-PD-1 monoclonal antibody SHR-1210. Read More
LONDON – Having moved its lead antibody-drug conjugate (ADC) into phase I over the summer, ADC Therapeutics Sarl has raised $80 million in a private round to fund that program and to take six further products into the clinic. Read More
In another victory for biopharma, the Patent and Trademark Office (PTO) rejected a second inter partes review (IPR) petition filed against a drugmaker by a hedge fund manager. Read More
Aytu Bioscience Inc., of Englewood, Colo., closed the final tranche of its planned private placement convertible note financing, raising a total of about $5.1 million, which includes proceeds from two prior tranches totaling about $3.1 million. Read More
Baxalta Inc., of Bannockburn, Ill., filed SEC paperwork for a secondary offering of up to $1.45 billion of common stock of the company currently held by Baxter International Inc., of Deerfield, Ill. Read More
Crispr Therapeutics, of Basel, Switzerland, named Samarth Kulkarni chief business officer, and Michael Bruce senior vice president, program portfolio and alliance management. Read More
Intra-Cellular Therapies Inc., of New York, said results published in Biological Psychiatry from a phase II trial of ITI-007 in patients with schizophrenia showed the drug significantly improved symptoms in patients experiencing an acute exacerbation of schizophrenia at a dose of 60 mg daily, as demonstrated by a statistically significant separation from placebo on the Positive and Negative Syndrome Scale (PANSS) total score at four weeks, the primary endpoint. Read More
